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Background: Tobacco use is one of the most common preventable causes of death, but more than half of the
Chinese men still use tobacco products. Moreover, 63.6% of Chinese smokers have stated that they would not consider
quitting. Specialized and intensive smoking-cessation services are too expensive and passive to have major clinical and
public health impacts in developing countries like China. Smoking cessation medications are not covered by medical
insurance, and their high price prevents Chinese smokers from using them. Brief interventions are needed to provide
cost-effective and timesaving tobacco dependence treatments in China mainland.
Methods/design: We describe a two-arm randomized controlled trial for smokers who have no intention to quit. The
project will be conducted in outpatient clinics at a large hospital in Beijing, China. Both arms include one face-to-face
interview plus five follow-up interventions. Each intervention will last approximately one minute. Subjects allocated to
the smoking-reduction intervention arm (SRI) will be advised to reduce smoking consumption to at least half of their
current consumption level within the next month. All subjects in the SRI will be warned to bear in mind that an
attempt to reduce smoking is an intermediate step before complete cessation. Smokers who have successfully reduced
their smoking consumption will be encouraged to completely cease smoking. Controls are subjects allocated to the
exercise- and diet-advice arm (EDA) and will be given advice about healthy diet and physical activity, but the advice will
not include smoking cessation or reduction. Data collection will be done at baseline and at each follow-up interview
using standardized questionnaires. The primary outcomes include self-reported and biochemically verified 7-day point
prevalence and prolonged abstinence rates at 12-month follow-up.
Discussion: We expect that an intention to quit in smoking outpatients can be motivated by physicians in the clinic
setting. If this very brief smoking-reduction intervention can be demonstrated to have a positive impact on long-term
smoking cessation, this strategy has the potential to be a viable and acceptable approach and may be used widely in
China and elsewhere.
Clinical trial registration: ClinicalTrials.gov: NCT02370147 (date of registration: 23th February, 2015).
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Tobacco use is one of the most common preventable
causes of death, and many countries are expending effort to
reduce the smoking prevalence. However, the prevalence of
smoking in China has declined little in recent years. The
Global Adult Survey reported that the prevalence of smok-
ing among Chinese men decreased from 57.4% in 2002 to
52.9% in 2010 [1,2]; thus, more than half of Chinese men
are still current smokers. Although quitting can reduce
the mortality due to smoking-induced diseases, 63.6% of
Chinese smokers would not consider quitting [2]. There-
fore, it is critical to expand smoking prevention and cessa-
tion efforts in China.
In developed countries and regions, including Hong
Kong and Taiwan with mostly Chinese [3-6], smoking ces-
sation services, such as smoking cessation clinics and tele-
phone quitlines, are well established. These services play
an important role in public health. However, these special-
ized and intensive smoking-cessation services are too
expensive and passive to have major clinical and public
health impacts in developing countries like China, as they
require continuous and enormous funding and intensive
training for counselors, and involve other costs, such as
pharmacotherapy. Pharmacotherapy is an effective treat-
ment modality for tobacco dependence, but it is not widely
used in China mainland [7,8]. One of the most important
reasons why pharmacotherapy is not widely used for smok-
ing cessation is that smoking-cessation medications are not
covered by medical insurance, and they are too expensive.
Hence, there is an urgent need for a much cheaper yet
effective strategy for helping smokers to quit.
In general, commonly used behavioral intervention cat-
egories fall into two categories: brief or minimal interven-
tions and intensive interventions [9]. A brief or minimal
intervention was defined in a Cochrane review as less than
20 minutes of advice plus up to one follow-up session [10];
other interventions were defined as intensive. Stead et al.
reported that the quit rate following brief advice from phy-
sicians was significantly higher than that following no ad-
vice (or usual care); the relative risk (RR) was 1.66, and the
95% confidence interval (CI) was 1.42 to 1.94 [10]. How-
ever, the quit rates following intensive counseling were not
found to be significantly different from those following brief
counseling in two Cochrane reviews [10,11]. As a result,
brief behavioral interventions are recommended to address
the need for cost-effective and timesaving interventions for
smokers [12]. In 2013, Lin et al. reported that their pilot
randomized controlled trial in Guangzhou, China showed
that a 30-second smoking cessation intervention by a phys-
ician was an effective way to encourage smokers to quit;
the 12-month continuous abstinence rate was 14.9%, com-
pared with 3.8% in the control group. These results suggest
that a very brief intervention can achieve a measurable
effect in China mainland [13,14].For smokers who have no intention to quit, smoking-
reduction interventions may be a therapeutic choice [15,16].
The common definition of successful smoking reduction is
a self-reported reduction of daily cigarette consumption
by 50% or more compared with baseline [17]. However,
smoking-reduction treatment has been highly contro-
versial in the past [18,19]. The main concerns and un-
certainties regarding this approach were that (a) a
short-term reduction may not be maintained for long
periods [20]; (b) smoking reduction does not necessarily
imply harm reduction [21-23]; and (c) future attempts
to quit smoking may be undermined by short-term re-
ductions in daily cigarette consumption [20]. However,
according to a meta-analysis by Asfar et al., pharmaco-
logical combined with smoking-reduction interventions
significantly increased long-term smoking cessation
rates by factors of 2.14 [19]. Recently, a randomized con-
trolled trial by Chan et al. also supported this conclusion
[24]. It has been reported that a smoking-reduction ap-
proach may be more likely to be adopted by a broader
range of smokers than traditional smoking-cessation inter-
ventions [25]. However, limited evidence exists about the
effectiveness of behavioral smoking-reduction randomized
controlled trials for smokers who have no intention to
quit. Glasgow et al. implemented an individual behavioral
smoking-reduction intervention for smokers who were
not interested in quitting smoking, and the results favored
the intervention but did not reach statistical significance
[26]. To our knowledge, no previous study has investi-
gated whether a very brief smoking-reduction intervention
can increase quitting rates in China; whether this ap-
proach is feasible and effective for increasing long-term
quit rates among smokers who have no intention to quit
remains unclear.
Brief interventions are needed to provide cost-effective
and timesaving treatments for tobacco dependence,
particularly in developing countries like China. The proto-
col described here is designed to fit the real life conditions
of China mainland. Smoking information should be rou-
tinely collected from outpatients in clinics; this interaction
provides a good opportunity for doctors to persuade out-
patients and their companions to quit smoking. A very
brief (i.e., approximately one-minute) smoking-reduction
intervention will be proposed to smokers who have no
intention to quit. All smokers receiving such intervention
will be asked to bear in mind that an attempt to reduce
smoking is an intermediate step before complete cessa-
tion. During follow-up interviews, if smokers have already
reduced their tobacco consumption, they will be encour-
aged to quit smoking during follow-up interviews. This
very brief, active and minimal cost individual smoking
reduction intervention will provide strong evidence for a
new approach for treating tobacco dependence in China
mainland and elsewhere.
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Study design
In the present protocol, we describe a two-arm randomized
controlled trial for smokers who have no intention to quit.
Participants, setting and procedure
The project will be conducted in the outpatient clinics of
the People's Liberation Army General Hospital in Beijing,
China. Physicians in outpatient clinics in the endocrin-
ology and acupuncture departments will be asked if they
want to participate in the trial. Those who agree to partici-
pate will be recruited into the current project. Before the
trial starts, the participating physicians will be trained.
Most of the physicians are in busy clinical settings, and
they may not be able to afford the extra few minutes
needed to advise each smoker to quit [14]; therefore, stu-
dents of the physicians will also be trained to assist with
completing the interviews.
Current smokers who are outpatients attending the
clinics and their companions will be included in the project.
Each self-reported smoker will be asked, “Do you have an
intention to quit smoking?” Smokers who answer that they
are “beginning to quit within the next 7 days” or “within 30
days” will be excluded from the trial. Smokers who answer
that they intend to quit “in the next 6 months” or “after 6
months” or that “I’m not making a decision about quitting
smoking” will be included in the trial [27,28].
Participants will be eligible for the study if they meet the
following criteria: (1) aged ≥18 years; (2) have smoked ≥10
cigarettes per day in the past month; (3) have no intention
to quit smoking; (4) agree to offer their telephone num-
bers and sign informed consent forms for participation.
Participants will be excluded from the study if they
meet the following criteria: (1) have smoked fewer than
10 cigarettes per day in the past month; (2) have a dis-
ease that makes a physician think it would be unethical
not to advise a patient to quit smoking as soon as pos-
sible; (3) are cognitively or otherwise impaired (i.e., deaf
or unable to understand and complete a questionnaire
reliably); (4) are pregnant or lactating females.
Signed, informed consent will be obtained from all
eligible participants. Information about the project aims,
interventions, assessments and data collection will be in-
cluded on a paper form. Eligible participants will also be
asked for a telephone number for follow-up interviews.
The study has been approved by the Independent Eth-
ics Committee of the Chinese People's Liberation Army
General Hospital.
Data collection
Data collection will be conducted at the first visit and at
each follow-up interview using standardized, structured
questionnaires. The questionnaires have been developed
based on questionnaires used in Hong Kong [3,29].Baseline data will be collected during the first visit via a
face-to-face interview. The collected data will include
demographic characteristics (gender, age, marital status
and educational level); self-reported perceived health sta-
tus over the past several days (very good, good, fair, poor,
very poor); smoking history (smoking status, the age at
starting smoking regularly and the average number of cig-
arettes smoked per day); the six questions regarding nico-
tine dependence levels based on the Fagerström Test for
Nicotine Dependence (FTND) [30]; past quitting history
(whether attempts have ever been made to quit, past use
of cessation products and causes of relapse); and whether
the participant has any doctor diagnosed chronic diseases.
Body weight will be measured in kilograms (shoes and
heavy clothing will be removed, and one kilogram will be
deducted for the participant’s remaining garments), and
exhaled carbon monoxide level will be measured using a
“Bedfont Micro II Smokerlizer” [3].
Follow-up data will be collected via telephone interviews
at 1 week and 1, 3, 6 and 12 months after the first inter-
view; questions will address smoking or smoking-reduction
status, quitting attempts and withdrawal symptoms. Partici-
pants who report having abstained from smoking for more
than 7 days at the 12-month follow-up will be invited to do
a face-to-face biochemical verification (i.e., exhaled carbon
monoxide level will be measured).
Randomization
Before participant recruitment, a research assistant on the
project will generate random numbers for group assign-
ments using a computer. If an individual is eligible to
participate in the study, and written consent is obtained,
trained counselors will randomly allocate the participant to
a treatment group by opening a serially labeled, opaque and
sealed envelope, and a card inside will indicate the group to
which the participant should be randomly allocated.
Blinding
Given the nature of the intervention, it will be impossible
to blind the subjects to their group assignments. However,
the trained counselors who will conduct the telephone
follow-up interviews will be different from the ones who
completed the first interview and will not know the aim of
the subjects; they will therefore be able to record outcome
measures with minimal subjective bias. The researchers
who will conduct the data analysis will be blinded to any
potential identifiers.
Sample-size calculation
Because no similar studies have previously been con-
ducted in China mainland, the effect-size estimation is
based on results from Hong Kong [14,24]. We assume
that the quit rate at the 12-month follow-up of the SRI
group would be 15% versus 5% for the control group. To
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would be needed for each group given an alpha level of
5% (two-sided) and a statistical power of 80%. A total of
331 participants will be recruited based on a possible loss
of 20% of the participants at the 12-month follow-up.
Description of the intervention
First, smokers who have an intention to quit will be advised
to quit immediately. Trained counselors will randomly
allocate the smokers who have no intention to quit into two
groups: the smoking-reduction intervention group (SRI) or
the exercise- and diet-advice group (EDA). The study design
of the current study is shown in Figure 1.
Smoking-reduction intervention group (SRI)
In the first face-to-face interview, trained counselors
will give each smoker a very brief smoking-reduction
intervention lasting approximately one minute. Smokers
will be warned that many non-communicable diseasesFigure 1 Study design. SRI: smoking-reduction intervention group; EDA: exare caused by smoking, such as cancer, coronary heart
disease, respiratory diseases and many other health prob-
lems. Moreover, one out of two smokers will be killed by
smoking [31]. Smokers will be advised to reduce smoking
consumption to at least half of their total consumption
within the next month. Finally, all smokers will be asked to
bear in mind that the current attempt to reduce smoking
would be an intermediate step before complete cessation.
The tobacco-use status of each smoker will be
assessed by another trained counselor who will not
know the aim of the project at 1 week and 1, 3, 6 and 12
months via telephone follow-ups. Additional smoking
cessation interventions will be given at each follow-up
according to their updated smoking status. Smokers will
be encouraged to reduce their smoking consumption
if they have not changed their smoking status, and
smokers who have successfully reduced their smoking
consumption will be encouraged to quit completely;
smokers who have successfully quit smoking will beercise- and diet-advice group.
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last for about one minute.
Exercise- and diet-advice group (EDA, Controls)
In the first face-to-face interview, trained counselors will
give each smoker very brief advice for about one minute.
Smokers will be advised to engage in regular physical activ-
ity three or four times per week and to have a healthy and
balanced diet including more fruits and vegetables, which
are rich in vitamins, high in nutrition values and yet low in
calories.
The tobacco-use status of each smoker will be assessed at
each follow-up interview, similar to the SRI group. Smokers
will be advised to engage in regular physical activity and to
eat more fruits and vegetables. Each follow-up will last ap-
proximately one minute. Throughout the process, smoking
cessation or smoking reduction will not be mentioned.
Outcome assessments
The primary outcomes include self-reported and
biochemically verified 7-day point prevalence and pro-
longed abstinence rates at 12-month follow-up inter-
view. Participants who report being abstinent from
smoking for more than seven days will be invited to
complete an exhaled carbon monoxide and saliva-
content (measured by NicAlert) test at the 12-month
follow-up. A previous study in Hong Kong [32] sug-
gests that few (i.e., approximately 10%) smokers will
return for this test. As a result, we will use self-
reported quit rates as the primary outcome measure if
few smokers return.
The secondary outcome measures include smoking-
reduction rates (i.e., the number of cigarettes smoked per
day reduced by at least 50% compared to the baseline) and
predictors of successful quitting at the 12-month follow-
up, and at earlier follow-ups.
Data analysis
Epidata (3.1) will be used to perform double entry of the
collected data. We will use SPSS (IBM Corp. Armonk, NY,
USA) for Windows (version 19.0) for data analysis. Baseline
characteristics will be compared using chi-squared tests,
Mann-Whitney tests and t tests. Regression models will be
used to compare the outcomes of different interventions.
We will adjust for baseline differences by including the vari-
ables in the regression models if necessary. Smokers who
cannot be contacted during follow-up will be considered
non-quitters or non-reducers in an intention-to-treat (ITT)
analysis. For sensitivity analysis, subjects lost to follow-up
will be excluded for per protocol (PP) sensitivity analyses.
Discussion
The current protocol describes a two-arm randomized
controlled trial. We aim to test the long-term (1 year)effectiveness of a very brief behavioral smoking reduc-
tion intervention on smokers who have no intention to
quit.
Previous studies have used various definitions and time
frames to define an intention to quit, such as ‘not willing to
quit in the next four weeks’ [24], “uninterested in quitting
at that time” [26], “no intention to quit within the next
month” [33] or “not ready to quit” [34]. In the current trial,
we use a recognized theory that incorporates a stage-of-
change model (include pre-contemplation, contemplation,
preparation, action and maintenance) [19,27,28]. We define
pre-contemplators (will quit after 6 months or undecided
about quitting) and contemplators (will quit in the next 6
months) as “having no intention to quit.”
While it has been reported that few smokers have an
intention to quit in China [35], physicians should play an
important role in smoking cessation [36,37]. Physicians
have a good opportunity to advise outpatients when they
visit their clinics. We expect that more outpatients can be
motivated to quit by physicians in clinic settings. Trad-
itional smoking-cessation services often focus on smokers
who express an interest in quitting. Clearly, it will be more
effective for physicians to offer assistance to all smokers,
not only to those selected by motivation [38]. Different
methods of intervention should be used for smokers with
different smoking histories. If a very brief smoking-
reduction intervention is demonstrated to have a positive
impact on long-term smoking cessation, this strategy has
the potential to be a viable and acceptable approach that
could be used widely in China and elsewhere.
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